Helping projects
change the future
APPLY NOW

News

Pilot implementation of Primer Capital’s portfolio project

4 April 2018

Botkin.AI implements its AI-based clinical decision support system into a hospital located in the Murmansk Region.

Pilot implementation of Primer Capital’s portfolio project

Botkin.AI implements its AI-based clinical decision support system into a hospital located in the Murmansk Region.
 

Startup Tour 2018

7 March 2018

60 proposals were submitted as part of the Skolkovo Startup Tour in Yuzhno-Sakhalinsk, of which 17 were approved for a face-to-face review.

Startup Tour 2018

60 proposals were submitted as part of the Skolkovo Startup Tour in Yuzhno-Sakhalinsk, of which 17 were approved for a face-to-face review.
 

February stock market decline for Big Pharma: panic or reality?

27 February 2018

The beginning of February was marked by significant fluctuations in stock prices and indices at stock exchange markets. Vitaly Kolobov, Primer Capital’s Investment Project Manager, went into details of these changes.

February stock market decline for Big Pharma: panic or reality?

The beginning of February was marked by significant fluctuations in stock prices and indices at stock exchange markets. Vitaly Kolobov, Primer Capital’s Investment Project Manager, went into details of these changes.
 

Private medical investments as industry growth drivers

26 February 2018

Read the interview of Elizaveta Rozhdestvenskaya, Primer Capital’s COO, to the Medical News Agency.

Private medical investments as industry growth drivers

Read the interview of Elizaveta Rozhdestvenskaya, Primer Capital’s COO, to the Medical News Agency.
 

TOP 3 most risky and promising areas of biotech

7 February 2018

Primer Capital’s Investment Project Manager Vitaly Kolobov shared his view on some of the things that a “non-profile” investor should keep in mind when investing in biotech.

TOP 3 most risky and promising areas of biotech

Primer Capital’s Investment Project Manager Vitaly Kolobov shared his view on some of the things that a “non-profile” investor should keep in mind when investing in biotech.
 

Why pharmaceutical companies abandon the development of important drugs?

22 January 2018

Yuriy Chirgadze wrote a column about pharmaceutical companies closing their drug development programs that they have been investing in for many years.

Why pharmaceutical companies abandon the development of important drugs?

Yuriy Chirgadze wrote a column about pharmaceutical companies closing their drug development programs that they have been investing in for many years.
 

Primer Capital invests in drug for ischemic stroke

16 January 2018

The total amount of the round, including the grant financing, investments from Primer Capital, other funds and private investors, is EUR 3.9 million.

Primer Capital invests in drug for ischemic stroke

The total amount of the round, including the grant financing, investments from Primer Capital, other funds and private investors, is EUR 3.9 million.
 

How passion for math and biology brought COO Primer Capital to the venture industry

9 January 2018

Elizaveta Rozhdestvenskaya told Firrma how she started in the venture business, whose life example inspires her and what her typical day looks like.

How passion for math and biology brought COO Primer Capital to the venture industry

Elizaveta Rozhdestvenskaya told Firrma how she started in the venture business, whose life example inspires her and what her typical day looks like.
 

FK Laboratoriz successfully completes pre-clinical development of a medication for treatment and prevention of thrombosis

26 December 2017

FK Laboratoriz, a project company in Primer Capital’s portfolio, has completed pre-clinical trials of a new original molecula under the contract with the Russian Ministry of Education and Science as part of Pharma-2020 Federal Target Program.

FK Laboratoriz successfully completes pre-clinical development of a medication for treatment and prevention of thrombosis

FK Laboratoriz, a project company in Primer Capital’s portfolio, has completed pre-clinical trials of a new original molecula under the contract with the Russian Ministry of Education and Science as part of Pharma-2020 Federal Target Program.
 

‘Smart money’ in biotech

22 December 2017

Primer Capital’s Investment Director Olga Tsyuryupa told Forbes how the ‘smart money’ approach minimizes risks of venture capitalists investing in biotech projects.

‘Smart money’ in biotech

Primer Capital’s Investment Director Olga Tsyuryupa told Forbes how the ‘smart money’ approach minimizes risks of venture capitalists investing in biotech projects.

Записи 1 - 10 of 20
First | Prev. | 1 2 | Next | Last